Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance
Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
